Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Profit After Tax: 2023-2025

Historic Profit After Tax for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' Profit After Tax rose 19.62% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 109.45%. This contributed to the annual value of $1.7 billion for FY2024, which is 799.19% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' Profit After Tax stood at -$35.3 million, which was down 23.04% from -$28.7 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Profit After Tax ranged from a high of $1.9 billion in Q2 2024 and a low of -$93.6 million during Q4 2023.
  • Its 3-year average for Profit After Tax is $138.6 million, with a median of -$45.9 million in 2024.
  • In the last 5 years, Inhibrx Biosciences' Profit After Tax surged by 3,898.37% in 2024 and then crashed by 101.54% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Profit After Tax (Quarterly) stood at -$93.6 million in 2023, then surged by 48.86% to -$47.9 million in 2024, then climbed by 19.62% to -$35.3 million in 2025.
  • Its Profit After Tax was -$35.3 million in Q3 2025, compared to -$28.7 million in Q2 2025 and -$43.3 million in Q1 2025.